CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof

摘要

The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.

主权项

1. A humanized CD37-specific binding molecule, comprising from amino terminus to carboxyl terminus:
(i) a humanized heavy chain variable region, (ii) a linker as set forth in SEQ ID NO:229, (iii) a humanized light chain variable region, (iv) an IgG1 hinge, (v) a human IgG1 CH2 region, and (vi) a human IgG1 CH3 region, wherein (a) the humanized heavy chain variable region comprises from amino terminus to carboxyl terminus: a human heavy chain FR1, a heavy chain CDR1 as set forth in SEQ ID NO:63, a human heavy chain FR2, a heavy chain CDR2 as set forth in SEQ ID NO:65, a human heavy chain FR3, a heavy chain CDR3 as set forth in SEQ ID NO:67, 68 or 69, and a human heavy chain FR4, and (b) the humanized light chain variable region comprises from amino terminus to carboxyl terminus: a human light chain FR1, a light chain CDR1 as set forth in SEQ ID NO:61 or 62, a human light chain FR2, a light chain CDR2 as set forth in SEQ ID NO:64, a human light chain FR3, and a light chain CDR3 as set forth in SEQ ID NO:66, and a human light chain FR4.